Pages that link to "Q30600094"
Jump to navigation
Jump to search
The following pages link to PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses (Q30600094):
Displaying 50 items.
- CAR models: next-generation CAR modifications for enhanced T-cell function (Q26745600) (← links)
- CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas (Q26749139) (← links)
- Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects (Q26753082) (← links)
- Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy (Q26773309) (← links)
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors (Q26778759) (← links)
- Synthetic biology approaches to engineer T cells (Q26798366) (← links)
- In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination (Q26801403) (← links)
- CAR T Cell Therapy: A Game Changer in Cancer Treatment (Q26822769) (← links)
- Adoptive cell therapy for sarcoma (Q27009541) (← links)
- Targeting the tumor vasculature to enhance T cell activity (Q27026329) (← links)
- Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. (Q27330599) (← links)
- Toxicity and management in CAR T-cell therapy (Q28075314) (← links)
- Smart CARs engineered for cancer immunotherapy (Q28087236) (← links)
- Designing chimeric antigen receptors to effectively and safely target tumors (Q28088526) (← links)
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies (Q30827633) (← links)
- Molecular Imaging in Synthetic Biology, and Synthetic Biology in Molecular Imaging (Q31163315) (← links)
- Strategies to genetically engineer T cells for cancer immunotherapy (Q33655849) (← links)
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells (Q33671867) (← links)
- Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells (Q33833475) (← links)
- Biology and clinical application of CAR T cells for B cell malignancies (Q33907565) (← links)
- Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies (Q33940443) (← links)
- A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy (Q34044757) (← links)
- Versatile strategy for controlling the specificity and activity of engineered T cells (Q34045831) (← links)
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits (Q34046041) (← links)
- An oxygen sensitive self-decision making engineered CAR T-cell. (Q34047851) (← links)
- Masked Chimeric Antigen Receptor for Tumor-Specific Activation (Q34047878) (← links)
- Cancer CARtography: charting out a new approach to cancer immunotherapy. (Q34139468) (← links)
- The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors (Q34309388) (← links)
- Prospects for gene-engineered T cell immunotherapy for solid cancers. (Q34507561) (← links)
- Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection (Q34517676) (← links)
- DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma (Q35209066) (← links)
- Current advances in T-cell-based cancer immunotherapy (Q35215158) (← links)
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity (Q35216278) (← links)
- Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma (Q35598804) (← links)
- IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. (Q35690979) (← links)
- Seatbelts in CAR therapy: How Safe Are CARS? (Q35818365) (← links)
- The quest for spatio-temporal control of CAR T cells (Q35843767) (← links)
- Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy (Q36173500) (← links)
- Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity (Q36218880) (← links)
- Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy (Q36830759) (← links)
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells (Q37066770) (← links)
- Chimeric antigen receptor-redirected T cells return to the bench (Q37301510) (← links)
- A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy (Q37555940) (← links)
- CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside (Q37559401) (← links)
- Chimaeric antigen receptor T-cell therapy for tumour immunotherapy (Q37609801) (← links)
- New development in CAR-T cell therapy (Q37658246) (← links)
- Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer (Q38198742) (← links)
- Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses. (Q38218786) (← links)
- Current Studies of Immunotherapy on Glioblastoma (Q38262914) (← links)
- Overcoming the toxicity hurdles of genetically targeted T cells (Q38285543) (← links)